Xenon Pharmaceuticals presents 'positive' XEN1101 Phase 1 data
Xenon Pharmaceuticals presented positive interim data from its ongoing XEN1101 Phase 1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain. XEN1101 is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy including: treatment-resistant adult and pediatric focal seizures as well as rare, pediatric forms of epilepsy, such as EIEE7, an early infantile epileptic encephalopathy associated with mutations in the KCNQ2 gene encoding the Kv7.2 potassium channel; and potentially other neurological disorders. Xenon presented interim data from its ongoing XEN1101 Phase 1 clinical trial, which is evaluating the safety, tolerability and pharmacokinetics of both single ascending doses and multiple ascending doses of XEN1101 in healthy subjects, along with results from the completed Phase 1a pilot transcranial magnetic stimulation study in 8 healthy subjects. The pilot TMS study was designed to assess XEN1101's ability to inhibit cortical excitability, an important CNS effect observed with anti-epileptic drugs. Based on this pilot Phase 1a TMS study, Xenon has initiated a double-blind, placebo-controlled, randomized cross-over Phase 1b TMS study, which is expected to include approximately 15 to 20 healthy subjects and be completed by mid-year, with data expected in the second half of 2018.